Publication | Closed Access

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)

Breast OncologyCancer ImmunosurveillanceDeath Ligand 1Therapeutic CandidateImmune Checkpoint InhibitorsImmunologyImmune Checkpoint InhibitorBreast CancerCancer TreatmentImmunotherapyMedicineCell BiologyTumor MicroenvironmentTumor Biology